Royalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher

Plus, news about Pacira Biosciences, Cassava Sciences, Merck, Monopar Therapeutics, Eli Lilly and Optinose:

Royalty Pharma signs MS deal: The company will pay about $525 million in cash to buy the milestones and royalties that ImmuNext is set to receive from Sanofi for a Phase 3 multiple sclerosis drug. Sanofi is expected to seek FDA approval of the monoclonal antibody in 2027. If frexalimab is approved, Royalty expects to get royalties from the drug through 2041. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Conducting trials via routine clinical practice: FDA explains how in new draft guidance

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 18, 2024

Racial discrimination may exacerbate obesity risk in children

Children who experience racial discrimination are more likely to later have a higher body mass index (BMI) and larger waistline, according to a new study

July 11, 2023

Canadian guideline expands treatment options for opioid use disorder

An updated evidence-based guideline aimed at helping clinicians and other health care providers manage patients with opioid use disorder recommends buprenorphine and methadone as first-line

November 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.